Happel David 4

What Happened David Happel, President & CEO and a director of Sagimet Biosciences (SGMT), received equity awards on February 19, 2026: 128,000 restricted stock units (RSUs) and 256,000 derivative awards (an option-style award). Both grants are reported with an acquisition price of $0.00 on the Form 4 (i.e., awards, not purchases).

Key Details

• Transaction date: February 19, 2026; Form 4 filed February 20, 2026 (appears timely — within the usual two-business-day window).
• Awards: 128,000 RSUs (F1) and 256,000 derivative awards/options (A, derivative).
• Reported price/value on Form 4: $0.00 for each grant (represents grant/acquisition, not market value).
• Vesting: RSUs vest in four equal annual installments beginning Feb 19, 2026 (F1). The derivative/option award vests and becomes exercisable in 48 equal monthly installments beginning Feb 19, 2026 (F2).
• Shares owned after the transaction: Not specified in the filing.
• No indication in this filing of immediate sale, tax withholding, 10b5‑1 plan, or late filing.

Context These entries are compensatory awards — RSUs give a contingent right to receive shares upon vesting, and the derivative award is an option-like grant that vests monthly. Such grants are common for executive compensation and do not represent an open‑market purchase or sale. The Form 4 reports the grant terms and vesting schedule; it does not disclose exercise prices or the awards' current market value.